Valneva SE (VALN)

NasdaqGS: VALN · Real-Time Price · USD

6.96

+0.14 (2.05%)

At close: Aug 21, 2026, 8:00 PM

6.96

+0.00%

After-hours: 4:10 PM

The price, the headline numbers and the latest news, in one place.

2.05% (1D)

No data available

Bid	6.91
Market Cap	659.97M
Revenue (ttm)	142.94M
Net Income (ttm)	-157.65M
	1.35
	-2.08
	n/a
	5.85
P/B (ttm)	7.03
P/S (ttm)	4.62
Earnings Date	Mar 17, 2027

Ask	7
Volume	21,540
Avg. Volume (20D)	78,762
Open	6.77
Previous Close	6.82
Day's Range	6.71 - 7.06
52-Week Range	4.75 - 12.23
Analyst	Buy
Price Target	13 (86.78%)
Dividends	n/a
Ex-Dividend Date	n/a

About VALN

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile toxin producing enterotoxigenic Escherichia coli bac...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date May 5, 2021

Employees 620

Stock Exchange NasdaqGS

Ticker Symbol VALN

Website https://valneva.com

Full Company Profile

Financial Performance

In 2025, Valneva SE's revenue was 174.66M, an increase of 3% compared to the previous year's 169.58M. Earnings were -115.19M, an increase of 840.57%.

Financial Statements

Analyst Forecast

According to 4 analyst ratings, the average rating for VALN stock is "Buy". The 12-month stock price forecast is 13, which is upside of 86.78% from the latest price.

Stock Forecasts

Earnings Surprise

Valneva SE has released their quarterly earnings on Aug 12, 2026:

Revenue of $30.9M misses estimates by $0, with -37.23% YoY decline.

EPS of -0.4 misses estimates by -0.32, with -150.00% YoY decline.

Next Earnings Release

Valneva SE is scheduled to release its earnings on Mar 17, 2027, before market opens.
Analysts project revenue of ... Upgrade

News

3 days ago · Simply Wall St.

Pfizer (PFE) Gets EMA Lyme Vaccine Filing Validation As ADC Patent Clout Grows

Pfizer (NYSE:PFE) and Valneva had their Marketing Authorization Application for a Lyme disease vaccine candidate validated by the European Medicines Agency, confirming it is ready for full review. The...

6 days ago · Simply Wall St.

Pfizer (PFE) Stock Looks Reasonable On Returns But Stretched On Earnings

Pfizer stock has delivered a roughly 28% decline over the past five years, yet recent gains and a mixed set of valuation checks mean the current price is not an obvious bargain or clear bubble. With f...